litlas
Log inCreate account

Melinda E. Sanders

Active 2002–2025

89
Papers
26,852
Citations
63
h-index
86
i10-index

Citations

Citations per year for Melinda E. Sanders1945: 1 citations1974: 1 citations1984: 1 citations1996: 1 citations1999: 1 citations2001: 1 citations2002: 1 citations2003: 5 citations2004: 15 citations2005: 19 citations2006: 31 citations2007: 27 citations2008: 39 citations2009: 22 citations2010: 45 citations2011: 44 citations2012: 51 citations2013: 101 citations2014: 125 citations2015: 206 citations2016: 226 citations2017: 313 citations2018: 415 citations2019: 1,269 citations2020: 1,589 citations2021: 1,702 citations2022: 1,411 citations2023: 1,076 citations2024: 1,475 citations2025: 802 citations2026: 26 citations1946–1973: no citations, so these years are not shown1975–1983: no citations, so these years are not shown1985–1995: no citations, so these years are not shown1997–1998: no citations, so these years are not shown2000: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,748 citing papers, 25.9% of this breakdownChina: 2,659 citing papers, 18.4% of this breakdownItaly: 654 citing papers, 4.5% of this breakdownUnited Kingdom: 650 citing papers, 4.5% of this breakdownGermany: 568 citing papers, 3.9% of this breakdownFrance: 468 citing papers, 3.2% of this breakdownCanada: 393 citing papers, 2.7% of this breakdownAustralia: 372 citing papers, 2.6% of this breakdownSpain: 347 citing papers, 2.4% of this breakdownSouth Korea: 336 citing papers, 2.3% of this breakdownIndia: 325 citing papers, 2.3% of this breakdownJapan: 319 citing papers, 2.2% of this breakdown
0%25.9%Other 25.1%

Institutions

Fields

  • Medicine44.8%
  • Biochemistry, Genetics and Molecular Biology41.1%
  • Immunology and Microbiology4.9%
  • Chemistry3.3%
  • Engineering1.8%
  • Computer Science1.6%
  • Other2.5%

Topics

  • Cancer Immunotherapy and Biomarkers6.2%
  • Cancer Cells and Metastasis4.3%
  • Breast Cancer Treatment Studies3.7%
  • Cancer Genomics and Diagnostics3.3%
  • Immunotherapy and Immune Responses2.8%
  • Advanced Breast Cancer Therapies2.6%
  • Other77.1%

Coauthors

All papers

Open in search
  1. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

    Authors: Brian D. Lehmann, Joshua A. Bauer, Xi Chen, Melinda E. Sanders, A. Bapsi Chakravarthy, Yu Shyr, Jennifer A. Pietenpol - Journal of Clinical Investigation 2011 cited by 5,515

  2. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

    Authors: Giampaolo Bianchini, Justin M. Balko, Ingrid A. Mayer, Melinda E. Sanders, Luca Gianni - Nature Reviews Clinical Oncology 2016 cited by 3,072

  3. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

    Authors: Francesca Finotello, Clemens Mayer, Christina Plattner, Gerhard Laschober, Dietmar Rieder, Hubert Hackl, Anne Krogsdam, Zuzana Loncová, Wilfried Posch, Doris Wilflingseder, Sieghart Sopper, Marieke E. Ijsselsteijn, Thomas P. Brouwer, Douglas B. Johnson, Yaomin Xu, Yu Wang, Melinda E. Sanders, Mónica V. Estrada, Paula I. González-Ericsson, Pornpimol Charoentong, Justin M. Balko, Noel F.C.C. de Miranda, Zlatko Trajanoski - Genome Medicine 2019 cited by 1,681

  4. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

    Authors: Brian D. Lehmann, Bojana Jovanović, Xi Chen, Mónica V. Estrada, Kimberly N. Johnson, Yu Shyr, Harold L. Moses, Melinda E. Sanders, Jennifer A. Pietenpol - PLoS ONE 2016 cited by 1,409

  5. Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities

    Authors: Suhas Vasaikar, Chen Huang, Xiaojing Wang, Vladislav Petyuk, Sara R. Savage, Bo Wen, Yongchao Dou, Yun Zhang, Zhiao Shi, Osama A. Arshad, Marina A. Gritsenko, Lisa J. Zimmerman, Jason McDermott, Therese RW Clauss, Ronald Moore, Rui Zhao, Matthew Monroe, Yi-Ting Wang, Matthew Chambers, Robbert J.C. Slebos, Ken S. Lau, Qianxing Mo, Li Ding, Matthew J. Ellis, Mathangi Thiagarajan, Christopher R. Kinsinger, Henry Rodriguez, Richard Smith, Karin Rodland, D.C. Liebler, Tao Liu, Bing Zhang, Akhilesh Pandey, Amanda G. Paulovich, Andrew N. Hoofnagle, D.R. Mani, Daniel W. Chan, David F. Ransohoff, David Fenyö, David L. Tabb, Douglas A. Levine, Emily S. Boja, Eric Kuhn, Forest M. White, Gordon A. Whiteley, Heng Zhu, Hui Zhang, Ie‐Ming Shih, Jasmin Bavarva, Jeffrey R. Whiteaker, Karen A. Ketchum, Karl R. Clauser, Kelly V. Ruggles, Kimberly Elburn, Linda I. Hannick, Mark A. Watson, Mauricio Oberti, Mehdi Mesri, Melinda E. Sanders, Melissa Borucki, Michael A. Gillette, M Snyder, Nathan Edwards, Negin Vatanian, Paul A. Rudnick, Peter B. McGarvey, Philip Mertins, R. Reid Townsend, Ratna R. Thangudu, Robert Rivers, Samuel Payne, Sherri R. Davies, Shuang Cai, Stephen E. Stein, Steven A. Carr, Steven J. Skates, Subha Madhavan, Tara Hiltke, Xian Chen, Yingming Zhao, Yue Wang, Zhen Zhang - Cell 2019 cited by 862

  6. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

    Authors: Kyung‐min Lee, Jennifer M. Giltnane, Justin M. Balko, Luis J. Schwarz, Ángel Guerrero‐Zotano, Katherine E. Hutchinson, Mellissa J. Nixon, Mónica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Taekyu Lee, Henry Gómez, Aňa Lluch, José Alejandro Pérez Fidalgo, Melissa M. Wolf, Gabriela Andrejeva, Jeffrey C. Rathmell, Stephen W. Fesik, Carlos L. Arteaga - Cell Metabolism 2017 cited by 646

  7. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy

    Authors: Karsten Krug, Eric J. Jaehnig, Shankha Satpathy, Lili M. Blumenberg, Alla Y. Karpova, Meenakshi Anurag, George Miles, Philipp Mertins, Yifat Geffen, Lauren C. Tang, David I. Heiman, Song Cao, Yosef E. Maruvka, Jonathan T. Lei, Chen Huang, Ramani Kothadia, Antonio Colaprico, Chet Birger, Jarey H. Wang, Yongchao Dou, Bo Wen, Zhiao Shi, Yuxing Liao, Maciej Wiznerowicz, Matthew A. Wyczalkowski, Xi Chen, Jacob J. Kennedy, Amanda G. Paulovich, Mathangi Thiagarajan, Christopher R. Kinsinger, Tara Hiltke, Emily S. Boja, Mehdi Mesri, Ana I. Robles, Henry Rodriguez, Thomas F. Westbrook, Li Ding, Gad Getz, Karl R. Clauser, David Fenyö, Kelly V. Ruggles, Bing Zhang, D.R. Mani, Steven A. Carr, Matthew J. Ellis, Michael A. Gillette, Shayan C. Avanessian, Shuang Cai, Daniel Chan, Xian Chen, Nathan Edwards, Andrew N. Hoofnagle, M. Harry Kane, Karen A. Ketchum, Eric Kuhn, Douglas A. Levine, Shunqiang Li, D.C. Liebler, Tao Liu, Jingqin Luo, Subha Madhavan, Christopher G. Maher, Jason McDermott, Peter B. McGarvey, Mauricio Oberti, Akhilesh Pandey, Samuel Payne, David F. Ransohoff, Robert Rivers, Karin Rodland, Paul A. Rudnick, Melinda E. Sanders, Kenna M. Shaw, Ie‐Ming Shih, Robbert J.C. Slebos, Richard Smith, M Snyder, Stephen E. Stein, David L. Tabb, Ratna R. Thangudu, Stefani N. Thomas, Yue Wang, Forest M. White, Jeffrey R. Whiteaker, Gordon A. Whiteley, Hui Zhang, Zhen Zhang, Yingming Zhao, Heng Zhu, Lisa J. Zimmerman - Cell 2020 cited by 575

  8. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer

    Authors: Hui Zhang, Tao Liu, Zhen Zhang, Samuel Payne, Bai Zhang, Jason McDermott, Jianying Zhou, Vladislav Petyuk, Li Chen, Debjit Ray, Shisheng Sun, Feng Yang, Lijun Chen, Jing Wang, Punit Shah, Seong Won, Paul Aiyetan, Sunghee Woo, Yuan Tian, Marina A. Gritsenko, Therese RW Clauss, Caitlin H. Choi, Matthew Monroe, Stefani N. Thomas, Song Nie, Chaochao Wu, Ronald Moore, Kun‐Hsing Yu, David L. Tabb, David Fenyö, Vineet Bafna, Yue Wang, Henry Rodriguez, Emily S. Boja, Tara Hiltke, Robert Rivers, Lori J. Sokoll, Heng Zhu, Ie‐Ming Shih, Leslie Cope, Akhilesh Pandey, Bing Zhang, M Snyder, Douglas A. Levine, Richard Smith, Daniel W. Chan, Karin Rodland, Steven A. Carr, Michael A. Gillette, Karl R. Klauser, Eric Kuhn, D.R. Mani, Philipp Mertins, Karen A. Ketchum, Ratna R. Thangudu, Shuang Cai, Mauricio Oberti, Amanda G. Paulovich, Jeffrey R. Whiteaker, Nathan Edwards, Peter B. McGarvey, Subha Madhavan, Pei Wang, Daniel W. Chan, Akhilesh Pandey, Ie‐Ming Shih, Hui Zhang, Zhen Zhang, Heng Zhu, Leslie Cope, Gordon A. Whiteley, Steven J. Skates, Forest M. White, Douglas A. Levine, Emily S. Boja, Christopher R. Kinsinger, Tara Hiltke, Mehdi Mesri, Robert Rivers, Henry Rodriguez, Kenna M. Shaw, Stephen E. Stein, David Fenyö, Tao Liu, Jason McDermott, Samuel Payne, Karin Rodland, Richard Smith, Paul A. Rudnick, M Snyder, Yingming Zhao, Xian Chen, David F. Ransohoff, Andrew N. Hoofnagle, D.C. Liebler, Melinda E. Sanders, Zhiao Shi, Robbert J.C. Slebos, David L. Tabb, Bing Zhang and 10 more - Cell 2016 cited by 1,126

  9. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

    Authors: Douglas B. Johnson, Mónica V. Estrada, Roberto Salgado, Violeta Sánchez, Deon B. Doxie, Susan R. Opalenik, Anna E. Vilgelm, Emily Feld, Adam S. Johnson, Allison R. Greenplate, Melinda E. Sanders, Christine M. Lovly, Dennie T. Frederick, Mark C. Kelley, Ann Richmond, Jonathan M. Irish, Yu Shyr, Ryan J. Sullivan, Igor Puzanov, Jeffrey A. Sosman, Justin M. Balko - Nature Communications 2016 cited by 572

  10. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

    Authors: Brian D. Lehmann, Antonio Colaprico, Tiago C. Silva, Jianjiao Chen, Hanbing An, Yuguang Ban, Hanchen Huang, Lily Wang, Jamaal L. James, Justin M. Balko, Paula I. González-Ericsson, Melinda E. Sanders, Bing Zhang, Jennifer A. Pietenpol, X. Steven Chen - Nature Communications 2021 cited by 260

  11. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research

    Authors: Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A. Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen Van de Vijver, Mónica V. Estrada, Paula I. González-Ericsson, Melinda E. Sanders, Benjamin Solomon, Cinzia Solinas, Gert G. G. M. Van den Eynden, Yves Allory, Matthias Preusser, Johannes A. Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, Fraser Symmans, Paolo Nucíforo, Laura Comerma, E. Aubrey Thompson, Sunil R. Lakhani, Seong-Rim Kim, Stuart J. Schnitt, Cécile Colpaert, Christos Sotiriou, Stefan Scherer, Michail Ignatiadis, Sunil Badve, Robert H. Pierce, Giuseppe Viale, Nicolas Sirtaine, Frédérique Penault‐Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok Srinivasan, Andrea L. Richardson, Yihong Wang, Ewa Chmielik, Jane B. Brock, Douglas B. Johnson, Justin M. Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternès, Nicole Burchardi, Stephen J. Luen, Peter Savas, Frederick Klauschen, Peter H. Watson, Brad H. Nelson, Carmen Criscitiello, Sandra A. O’Toole, Denis Larsimont, Roland de Wind, Giuseppe Curigliano, Fabrice André, Magali Lacroix‐Triki, Marc J. van de Vijver, Federico Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph A. Sparano, David L. Rimm, Torsten O. Nielsen, Zuzana Kos, Stephen M. Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H. Allison, Nadine Tung, Sylvia Adams, Karen Willard‐Gallo, Hugo M. Horlings, Leena Gandhi, André L. Moreira, Fred R. Hirsch, Maria Vittoria Dieci, María Urbanowicz, Iva Brčić, Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer M. Giltnane, Marlon C. Rebelatto, Keith E. Steele, Jiping Zha, Kenneth Emancipator, Jonathan Juco, Carsten Denkert, Jorge S. Reis‐Filho, Sherene Loi, Stephen B. Fox - Advances in Anatomic Pathology 2017 cited by 720

  12. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer

    Authors: Na Luo, Mellissa J. Nixon, Paula I. González-Ericsson, Violeta Sánchez, Susan R. Opalenik, Huili Li, Cynthia A. Zahnow, Michael L. Nickels, Fei Liu, Mohammed Noor Tantawy, Melinda E. Sanders, H. Charles Manning, Justin M. Balko - Nature Communications 2018 cited by 271

  13. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

    Authors: Luigi Formisano, Yao Lu, Alberto Servetto, Ariella B. Hanker, Valerie M. Jansen, Joshua A. Bauer, Dhivya R. Sudhan, Ángel Guerrero‐Zotano, Sarah Croessmann, Yan Guo, Paula I. González-Ericsson, Kyung‐min Lee, Mellissa J. Nixon, Luis J. Schwarz, Melinda E. Sanders, Teresa C. Dugger, Marcelo Cruz, Amir Behdad, Massimo Cristofanilli, Aditya Bardia, Joyce O’Shaughnessy, Rebecca J. Nagy, Richard B. Lanman, Nadia Solovieff, Wei He, Michelle C. Miller, Fei Su, Yu Shyr, Ingrid A. Mayer, Justin M. Balko, Carlos L. Arteaga - Nature Communications 2019 cited by 419

  14. Limiting mitochondrial plasticity by targeting DRP1 induces metabolic reprogramming and reduces breast cancer brain metastases

    Authors: Pravat Kumar Parida, Mauricio Marquez-Palencia, Suvranil Ghosh, Nitin Khandelwal, Kangsan Kim, Vidhya R. Nair, Xiao‐Zheng Liu, Hieu Vu, Lauren G. Zacharias, Paula I. González-Ericsson, Melinda E. Sanders, Bret C. Mobley, Jeffrey G. McDonald, Andrew Lemoff, Yan Peng, Cheryl Lewis, Gonçalo Vale, Nils Halberg, Carlos L. Arteaga, Ariella B. Hanker, Ralph J. DeBerardinis, Srinivas Malladi - Nature Cancer 2023 cited by 92

  15. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

    Authors: Susana García‐Recio, Toshinori Hinoue, Gregory Wheeler, Benjamin Kelly, Ana C. Garrido-Castro, Tomás Pascual, Aguirre A. de Cubas, Youli Xia, Brooke Felsheim, Marni B. McClure, Andrei Rajkovic, Ezgi Karaesmen, Markia A. Smith, Cheng Fan, Paula I. González-Ericsson, Melinda E. Sanders, Chad J. Creighton, Jay Bowen, Kristen Leraas, Robyn Burns, Sara E. Coppens, Amy Wheless, Salma Rezk, Amy Garrett, Joel S. Parker, Kelly K. Foy, Hui Shen, Ben Ho Park, Ian E. Krop, Carey K. Anders, Julie M. Gastier‐Foster, Mothaffar F. Rimawi, Rita Nanda, Nancy U. Lin, Claudine Isaacs, P. Kelly Marcom, Anna Maria Storniolo, Fergus J. Couch, Uma Chandran, Michael A. Davis, Jonathan C. Silverstein, Alexander J. Ropelewski, Minetta C. Liu, Susan G. Hilsenbeck, Larry Norton, Andrea L. Richardson, W. Fraser Symmans, Antonio C. Wolff, Nancy E. Davidson, Lisa A. Carey, Adrian V. Lee, Justin M. Balko, Katherine A. Hoadley, Peter W. Laird, Elaine R. Mardis, Tari A. King, AURORA US Network, Aguirre A. de Cubas, Charles M. Perou - Nature Cancer 2022 cited by 114

  16. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

    Authors: Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, S.E. Combs, David L. Rimm, Jennifer M. Giltnane, Mónica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, S. Mallal, Kai Wang, Vincent A. Miller, Phil Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko - Clinical Cancer Research 2015 cited by 552

  17. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

    Authors: Neil E. Bhola, Justin M. Balko, Teresa C. Dugger, M. Gabriela Kuba, Violeta Sánchez, Melinda E. Sanders, Jamie C. Stanford, Rebecca S. Cook, Carlos L. Arteaga - Journal of Clinical Investigation 2013 cited by 593

  18. Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness

    Authors: Pravat Kumar Parida, Mauricio Marquez-Palencia, Vidhya R. Nair, Akash Kaushik, Kangsan Kim, Jessica Sudderth, Eduardo Quesada-Diaz, Ámbar Cajigas, Vamsidhara Vemireddy, Paula I. González-Ericsson, Melinda E. Sanders, Bret C. Mobley, Kenneth E. Huffman, Sunati Sahoo, Prasanna Alluri, Cheryl Lewis, Yan Peng, Robert Bachoo, Carlos L. Arteaga, Ariella B. Hanker, Ralph J. DeBerardinis, Srinivas Malladi - Cell Metabolism 2022 cited by 104

  19. Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma

    Authors: Yingwei Hu, Jianbo Pan, Punit Shah, Minghui Ao, Stefani N. Thomas, Yang Liu, Lijun Chen, Michael Schnaubelt, David Clark, Henry Rodriguez, Emily S. Boja, Tara Hiltke, Christopher R. Kinsinger, Karin Rodland, Qing Kay Li, Jiang Qian, Zhen Zhang, Daniel W. Chan, Hui Zhang, Akhilesh Pandey, Amanda G. Paulovich, Andrew N. Hoofnagle, Bing Zhang, D.R. Mani, D.C. Liebler, David F. Ransohoff, David Fenyö, David L. Tabb, Douglas A. Levine, Eric Kuhn, Forest M. White, Gordon A. Whiteley, Heng Zhu, Ie‐Ming Shih, Jasmin Bavarva, Jason McDermott, Jeffrey R. Whiteaker, Karen A. Ketchum, Karl R. Clauser, Kelly V. Ruggles, Kimberly Elburn, Li Ding, Linda I. Hannick, Lisa J. Zimmerman, Mark A. Watson, Mathangi Thiagarajan, Matthew J. Ellis, Mauricio Oberti, Mehdi Mesri, Melinda E. Sanders, Melissa Borucki, Michael A. Gillette, M Snyder, Nathan Edwards, Negin Vatanian, Paul A. Rudnick, Peter B. McGarvey, Philip Mertins, R. Reid Townsend, Ratna R. Thangudu, Richard Smith, Robert Rivers, Robert J.C. Slebos, Samuel Payne, Sherri R. Davies, Shuang Cai, Stephen E. Stein, Steven A. Carr, Steven J. Skates, Subha Madhavan, Tao Liu, Xian Chen, Yingming Zhao, Yue Wang, Zhiao Shi - Cell Reports 2020 cited by 155

  20. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer

    Authors: Brian D. Lehmann, Vandana G. Abramson, Melinda E. Sanders, Erica L. Mayer, Tufia C. Haddad, Rita Nanda, Catherine Van Poznak, Anna Maria Storniolo, Julie R. Nangia, Paula I. González-Ericsson, Violeta Sánchez, Kimberly N. Johnson, Richard G. Abramson, Sheau‐Chiann Chen, Yu Shyr, Carlos L. Arteaga, Antonio C. Wolff, Jennifer A. Pietenpol - Clinical Cancer Research 2019 cited by 154

  21. NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer

    Authors: Brandie C. Taylor, Xiaopeng Sun, Paula I. González-Ericsson, Violeta Sánchez, Melinda E. Sanders, Elizabeth C. Wescott, Susan R. Opalenik, Ann Hanna, Shu-Ting Chou, Luc Van Kaer, Henry Gómez, Claudine Isaacs, Tarah J. Ballinger, Cesar A. Santa‐Maria, Payal D. Shah, Elizabeth Claire Dees, Brian D. Lehmann, Vandana G. Abramson, Jennifer A. Pietenpol, Justin M. Balko - Cancer Discovery 2023 cited by 63

  22. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

    Authors: Brian D. Lehmann, Joshua A. Bauer, Johanna M. Schafer, Christopher S Pendleton, Luojia Tang, Kimberly C. Johnson, Xi Chen, Justin M. Balko, Henry Gómez, Carlos L. Arteaga, Gordon B. Mills, Melinda E. Sanders, Jennifer A. Pietenpol - Breast Cancer Research 2014 cited by 331

  23. Quantitative Optical Imaging of Primary Tumor Organoid Metabolism Predicts Drug Response in Breast Cancer

    Authors: Alex J. Walsh, Rebecca S. Cook, Melinda E. Sanders, Luigi Aurisicchio, Gennaro Ciliberto, Carlos L. Arteaga, Melissa C. Skala - Cancer Research 2014 cited by 318

  24. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement

    Authors: Douglas B. Johnson, Mellissa J. Nixon, Yu Wang, Daniel Wang, Emily Castellanos, Mónica V. Estrada, Paula I. González-Ericsson, Candace H. Cote, Roberto Salgado, Violeta Sánchez, Phillip T. Dean, Susan R. Opalenik, Daniel M. Schreeder, David L. Rimm, Ju‐Young Kim, Jennifer Bordeaux, Sherene Loi, Leora Horn, Melinda E. Sanders, P. Brent Ferrell, Yaomin Xu, Jeffrey A. Sosman, Randall S. Davis, Justin M. Balko - JCI Insight 2018 cited by 159